Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a phase 3 randomized clinical trial in patients with narcolepsy

STUDY OBJECTIVES: To assess the efficacy and safety of FT218, a novel once-nightly formulation of sodium oxybate (ON-SXB), in patients with narcolepsy in the phase 3 REST-ON trial. METHODS: Narcolepsy patients aged ≥16 years were randomized 1:1 to uptitration of ON-SXB (4.5, 6, 7.5, and 9 g) or plac...

Descripción completa

Detalles Bibliográficos
Autores principales: Kushida, Clete A, Shapiro, Colin M, Roth, Thomas, Thorpy, Michael J, Corser, Bruce C, Ajayi, Akinyemi O, Rosenberg, Russell, Roy, Asim, Seiden, David, Dubow, Jordan, Dauvilliers, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Neurological Disorders
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189976/
https://www.ncbi.nlm.nih.gov/pubmed/34358324
http://dx.doi.org/10.1093/sleep/zsab200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189976/
https://www.ncbi.nlm.nih.gov/pubmed/34358324
http://dx.doi.org/10.1093/sleep/zsab200

Ejemplares similares